Top-tier fund specializing in early-stage biotechnology investments. Focused on North American and European markets, with a portfolio comprising over 15 deals. Achieved notable exits including several IPOs in the healthcare sector. Emphasizes operator-led strategies and strong mentorship for portfolio companies, maintaining a selective investment approach.